ProShare Advisors’s Tvardi Therapeutics TVRD Stock Holding History

ProShare Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-284	Closed	-$50.2K	–	1921
2023 Q1	$50.2K	Sell	284 -36	-11%	-$12.1K	﹤0.01%	1669
2022 Q4	$124K	Buy	320 +23	+8%	+$8.73K	﹤0.01%	1604
2022 Q3	$100K	Buy	297 +8	+3%	+$2.9K	﹤0.01%	1561
2022 Q2	$95K	Sell	289 -137	-32%	-$48.1K	﹤0.01%	1621
2022 Q1	$186K	Sell	426 -89	-17%	-$36.5K	﹤0.01%	1901
2021 Q4	$226K	Buy	515 +29	+6%	+$14.6K	﹤0.01%	1957
2021 Q3	$270K	Sell	486 -116	-19%	-$58.2K	﹤0.01%	1620
2021 Q2	$310K	Buy	602 +106	+21%	+$67.2K	﹤0.01%	1875
2021 Q1	$388K	Buy	496 +29	+6%	+$19.9K	﹤0.01%	1631
2020 Q4	$254K	Buy	467 +117	+33%	+$61.3K	﹤0.01%	1721
2020 Q3	$160K	Sell	350 -13	-4%	-$7.55K	﹤0.01%	1454
2020 Q2	$224K	Buy	+363	New	+$200K	﹤0.01%	1403
2020 Q1	–	Sell	-430	Closed	-$250K	–	1628
2019 Q4	$250K	Sell	430 -45	-9%	-$31.6K	﹤0.01%	1456
2019 Q3	$313K	Buy	475 +57	+14%	+$47.4K	﹤0.01%	1210
2019 Q2	$324K	Sell	418 -53	-11%	-$37.2K	﹤0.01%	1200
2019 Q1	$332K	Buy	471 +4	+0.9%	+$2.39K	﹤0.01%	1199
2018 Q4	$218K	Sell	467 -89	-16%	-$57.4K	﹤0.01%	1332
2018 Q3	$479K	Buy	556 +75	+16%	+$54.1K	﹤0.01%	1124
2018 Q2	$332K	Sell	481 -33	-6%	-$16.8K	﹤0.01%	1321
2018 Q1	$229K	Sell	514 -84	-14%	-$40.7K	﹤0.01%	1470
2017 Q4	$264K	Buy	+598	New	+$273K	﹤0.01%	1476
2016 Q4	–	Sell	-536	Closed	-$161K	–	1755
2016 Q3	$161K	Sell	536 -100	-16%	-$21.7K	﹤0.01%	1376
2016 Q2	$110K	Buy	636 +13	+2%	+$2.83K	﹤0.01%	1514
2016 Q1	$140K	Sell	623 -66	-10%	-$19.7K	﹤0.01%	1481
2015 Q4	$418K	Buy	689 +61	+10%	+$33.5K	0.01%	1122
2015 Q3	$323K	Buy	628 +63	+11%	+$42.2K	﹤0.01%	1113
2015 Q2	$247K	Buy	565 +26	+5%	+$10K	﹤0.01%	1392
2015 Q1	$195K	Buy	539 +88	+20%	+$33.3K	﹤0.01%	1726
2014 Q4	$162K	Buy	+451	New	+$145K	﹤0.01%	1781

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's TVRD Position: Q2 2023 in Review

ProShare Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 284 shares — an estimated $50.2K sold.

ProShare Advisors first reported a position in TVRD in Q4 2014 and held it in 29 quarters. The position peaked at $479K in Q3 2018. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

ProShare Advisors reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
ProShare Advisors sold 284 Tvardi Therapeutics shares in Q2 2023, an estimated $50.2K.
ProShare Advisors first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 29 quarters.
ProShare Advisors's Tvardi Therapeutics position peaked at $479K in Q3 2018.
136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on ProShare Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.